MX2021012035A - Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos. - Google Patents

Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos.

Info

Publication number
MX2021012035A
MX2021012035A MX2021012035A MX2021012035A MX2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A
Authority
MX
Mexico
Prior art keywords
agents
disease
deplete
antibodies
methods
Prior art date
Application number
MX2021012035A
Other languages
English (en)
Spanish (es)
Inventor
Chanty Mariategue Chan
Nenad Tomasevic
Panagiotis Fotakis
Ruo Shi Shi
Adam Lewis Salles
Original Assignee
Dren Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dren Bio Inc filed Critical Dren Bio Inc
Publication of MX2021012035A publication Critical patent/MX2021012035A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2021012035A 2019-04-05 2020-04-03 Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos. MX2021012035A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830139P 2019-04-05 2019-04-05
PCT/US2020/026721 WO2020206354A1 (en) 2019-04-05 2020-04-03 Methods of depleting disease causing agents via antibody targeted phagocytosis

Publications (1)

Publication Number Publication Date
MX2021012035A true MX2021012035A (es) 2022-03-11

Family

ID=72667025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012035A MX2021012035A (es) 2019-04-05 2020-04-03 Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos.

Country Status (12)

Country Link
US (2) US20220169737A1 (enExample)
EP (1) EP3947467A4 (enExample)
JP (2) JP2022527646A (enExample)
KR (1) KR20220031995A (enExample)
CN (1) CN114502585A (enExample)
AU (1) AU2020253621A1 (enExample)
BR (1) BR112021019950A2 (enExample)
CA (1) CA3136272A1 (enExample)
IL (1) IL286967A (enExample)
MX (1) MX2021012035A (enExample)
SG (1) SG11202110663UA (enExample)
WO (1) WO2020206354A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
WO2021222894A1 (en) 2020-05-01 2021-11-04 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibodies
MX2023004054A (es) 2020-10-07 2023-06-29 Dren Bio Inc Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
CN119301156A (zh) * 2022-04-04 2025-01-10 德伦生物公司 抗Dectin-1抗体和其使用方法
US20250223364A1 (en) * 2022-04-04 2025-07-10 Dren Bio, Inc. Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof
KR20260048578A (ko) * 2023-07-31 2026-04-10 드렌 바이오 매니지먼트, 인크. Dectin-1 및 TROP-2에 결합하는 다중특이적 결합 단백질 및 이의 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679949B (zh) * 2007-02-23 2015-08-19 贝勒研究院 通过dectin-1激活人抗原呈递细胞的治疗性应用
WO2012129227A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
WO2018176159A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
US12384850B2 (en) * 2017-06-25 2025-08-12 Systimmune, Inc. Guidance and navigation control proteins and method of making and using thereof
CA3106796A1 (en) * 2018-07-19 2020-01-23 Oncohost Ltd Il-31 improves efficacy of macrophage-based adoptive cell therapy for cancer
EA202190183A1 (ru) * 2018-07-27 2021-05-18 Алектор Ллс Антитела к siglec-5 и способы их применения

Also Published As

Publication number Publication date
US20250206826A1 (en) 2025-06-26
BR112021019950A2 (pt) 2021-12-07
US20220169737A1 (en) 2022-06-02
SG11202110663UA (en) 2021-10-28
JP2022527646A (ja) 2022-06-02
AU2020253621A1 (en) 2021-11-11
CA3136272A1 (en) 2020-10-08
CN114502585A (zh) 2022-05-13
EP3947467A4 (en) 2023-01-04
KR20220031995A (ko) 2022-03-15
IL286967A (en) 2021-12-01
JP2025096316A (ja) 2025-06-26
WO2020206354A1 (en) 2020-10-08
EP3947467A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
BR112021019950A2 (pt) Métodos de esgotamento de agentes causadores de doenças por meio de anticorpo de fagocitose alvejada
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
EP4276114A3 (en) Cd20 binding single domain antibodies
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
BR112015000657A2 (pt) métodos para depletar células b em um indivíduo, para promover tolerância em um indivíduo e para tratar doença do enxerto versus hospedeiro
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
EP3421488A3 (en) Multispecific antigen-binding molecules and uses thereof
SA523440623B1 (ar) أجسام مضادة
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
AR080564A1 (es) Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3)
SI2780368T1 (en) INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
UA94899C2 (ru) Фиксированное дозирование антител к her
BR112016029334A2 (pt) produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos
BRPI1010861A8 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
BR112014031028A2 (pt) Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista
BR112014008804A2 (pt) suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos
BR112021016296A2 (pt) Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
MX2022005904A (es) Composiciones y metodos para la activacion de integrinas.
EA202092136A1 (ru) Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
MX2021005085A (es) Formulacion de anticuerpo.